A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
19hon MSN
This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results